CIK 0000715446 · Non-accelerated filer<br>Smaller reporting company
Anixa Biosciences Inc
Sign in to watch- Ticker
- ANIX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Oct 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 112622630
- Phone
- 408-708-9808
- Business address
- 3150 ALMADEN EXPRESSWAY, SUITE 250, SAN JOSE, CA, 95118
- Former names
- ITUS Corp, COPYTELE INC
- 4 Open-market buy Chief Executive Officer bought 43,000 shares at $2.23 ($95,890)
- 4 Open-market buy President, COO, & CFO bought 9,289 shares at $2.15 ($19,971)
- S-8 Other Securities Offered to Employees in Benefit Plans
- 10-K Report Annual Report
- SCHEDULE 13D/A Stake Beneficial Ownership Report
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 8-K Event Regulation FD disclosure
- 4 Option exercise Director acquired 16,000 shares (option exercise)
- 10-Q Report Quarterly Report
- 4 Open-market buy Director bought 27,226 shares at an average $3.09 ($84,260)
- 4 Open-market buy Director bought 8,496 shares at an average $3.01 ($25,568)
- 4 Open-market buy Director bought 5,000 shares at $3.09 ($15,450)
- 4 Open-market buy Director bought 4,000 shares at $2.68 ($10,720)
- 4 Open-market buy Director bought 405 shares at $2.70 ($1,094)
- 4 Open-market buy Director bought 7,432 shares at an average $2.66 ($19,749)
- 4 Open-market buy Director bought 10,738 shares at $2.52 ($27,060)
Page 4 of 50 · 983 filings